knowledge -WSS

knowledge

author：focus 2025-09-29 19:07:02 - browse：47

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Study points to new risk in gene therapy death of Terry Horgan

WSS

The Karikó problem: Lessons for funding basic research

After Sarepta trial failure, Duchenne families brace for more debate

All of Us, NIH's precision medicine initiative, gets a big boost

Lung cancer screening guidelines updated for cigarette smokers

The United States is paying nearly triple for new Covid vaccines

Humans aren't the only ones with an imagination. Rats have it too

Wikipedia

knowledge

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Explaining an after

George Santos makes 1st court appearance after pleading not guilty to 13 counts

European officials brace for rough respiratory virus season

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare must police algorithms in Medicare Advantage, Dems say

Alkermes shareholders re

6 solutions to address cancer drug shortages and others

Novavax promises a turnaround & Lilly roils the obesity market

Stop Congress from blocking public access to science

Wikipedia

CRISPR base editing slashes cholesterol levels in monkeys

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Gene therapy’s promise and the high cost of hope

Explaining an after

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

knowledge

hotspot

explore

focus